NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak – What’s Driving Investors’ Enthusiasm Today?
Natera’s Signatera test secured a key regulatory approval, while Cantor raised its sales expectations for Omeros’ lead drug, Yartemlea. Natera expects to commercially launch the test in Japan in the first half of 2027 Cantor sees Yartemlea potentially capturing 30% to 40% of its market over time. Yartemlea generated $28.5 million in second-quarter net sales, … Read more